FDA approves Abbott drug for psoriasis

Humira approved to treat psoriasis, says Abbott; extra indication could add $500M to blockbuster's sales, analyst sales.

Subscribe to Companies
google my aol my msn my yahoo! netvibes
Paste this link into your favorite RSS desktop reader
See all CNNMoney.com RSS FEEDS (close)
By Aaron Smith, CNNMoney.com staff writer

NEW YORK (CNNMoney.com) -- The FDA approved Abbott's blockbuster drug Humira for yet another indication, psoriasis, the drugmaker said Friday.

The extra indication could add at least $500 million in annual sales to Humira, which is expected to total $3 billion in 2007, said Phillip Nalbone, analyst for RBC Capital Markets, who was interviewed just prior to the announcement.

Humira was already approved to treat psoriasis in Europe. In the U.S., Humira was already approved to treat four other diseases, including rheumatoid arthritis, psoriatic arthritis, an inflammation of the digestive tract called Crohn's disease and a spinal inflammation called ankylosing spondylitis.

Abbott (ABT, Fortune 500) made the announcement after the close of trading.

Abbott is the fourth-largest U.S. drugmaker in terms of annual sales, behind Johnson & Johnson (JNJ, Fortune 500), Pfizer (PFE, Fortune 500) and Merck (MRK, Fortune 500). To top of page

Photo Galleries
The median home price is $236,000. Here's what that buys you The median home price climbed to $236,400 in June, according to the National Association of Realtors. Here's what that will buy you across the United States. More
Affordable homes with water views Living by the water doesn't always have to set you back seven figures. More
Sponsors